These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 180408)

  • 1. Elevated plasma proglucagon-like component with a glucagon-secreting tumor. Effect of streptozotocin.
    Danforth DN; Triche T; Doppman JL; Beazley RM; Perrino PV; Recant L
    N Engl J Med; 1976 Jul; 295(5):242-5. PubMed ID: 180408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma.
    Valverde I; Lemon HM; Kessinger A; Unger RH
    J Clin Endocrinol Metab; 1976 May; 42(5):804-8. PubMed ID: 178682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial hyperglucagonemia--an autosomal dominant disorder.
    Boden G; Owen OE
    N Engl J Med; 1977 Mar; 296(10):534-8. PubMed ID: 189188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor.
    Del Prato S; Rovira A; Tessari P; Avogaro A; Nosadini R; Valverde I; Trevisan R; Tiengo A
    J Endocrinol Invest; 1984 Apr; 7(2):111-5. PubMed ID: 6327796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon secretion in rats with islet cell tumors induced by streptozotocin.
    Yoshino G; Kazumi T; Morita S; Kobayashi N; Terashi K; Baba S
    Horm Metab Res; 1980 Jan; 12(1):40-1. PubMed ID: 6244219
    [No Abstract]   [Full Text] [Related]  

  • 6. Metastatic pancreatic islet cell carcinoma causing manifestations of glucagon and gastrin hypersecretion.
    Ferrara JJ; Fucci JC; Benson JB
    Conn Med; 1985 Dec; 49(12):777-80. PubMed ID: 3002718
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunologic characterization of plasma glucagon components in a patient with malignant glucagonoma.
    Tanaka K; Watabe T; Shimizu N; Horiuchi T; Nakamura K; Yoshida H
    Metabolism; 1984 Aug; 33(8):728-33. PubMed ID: 6087085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Islet cell carcinoma of the pancreas: effective therapy with 5-fluorouracil, streptozotocin, and tubercidin.
    Kraybill WG; Anderson DD; Lindell TD; Fletcher WS
    Am Surg; 1976 Jul; 42(7):467-70. PubMed ID: 180857
    [No Abstract]   [Full Text] [Related]  

  • 9. [Nonfunctional langerhansian cancer with hepatic metastases. Treatment with streptozotocin].
    Piard A; Rifle C; Baudet JG
    Med Chir Dig; 1972; 1(3):119-22. PubMed ID: 4342930
    [No Abstract]   [Full Text] [Related]  

  • 10. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
    Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
    Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Insulin secreting islet cell carcinoma treated with streptozotocin (apropose of a case)].
    Chevrel JP; Amouroux J; Attali JR; Izou H
    Med Chir Dig; 1976; 5(1):25-31. PubMed ID: 189143
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of malignant metastatic pancreatic insulinoma with streptozotocin. Review of 21 cases described in detail in the literature and report of complete remission of a new case.
    Herbai G; Lundin A
    Acta Med Scand; 1976; 200(6):447-52. PubMed ID: 189576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of somatostatin in the Syrian hamster bearing a transplantable islet-cell tumor.
    Luyckx AS; Lefebvre PJ
    Horm Metab Res; 1978 Mar; 10(2):105-10. PubMed ID: 206496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Zollinger-Ellison syndrome and metastatic insulinoma; its response to streptozotocin].
    Agular-Parada E; Rivadeneyra-Hinojosa J; Guzman-Patraca C; Salas-Montero J; Escalante-Herrera A
    Arch Invest Med (Mex); 1977; 8(1):31-8. PubMed ID: 192163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic polypeptide-secreting islet-cell tumors. A study of three cases.
    Tomita T; Friesen SR; Kimmel JR; Doull V; Pollock HG
    Am J Pathol; 1983 Nov; 113(2):134-42. PubMed ID: 6314815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion by glucagonomas of a possible glucagon precursor.
    Weir GC; Horton ES; Aoki TT; Slovik D; Jaspan J; Rubenstein AH
    J Clin Invest; 1977 Feb; 59(2):325-30. PubMed ID: 833279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin and glucagon in rats with islet cell tumors induced by small doses of streptozotocin.
    Yoshino G; Kazumi T; Morita S; Baba S
    Can J Physiol Pharmacol; 1981 Aug; 59(8):818-23. PubMed ID: 6271376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucagonoma syndrome. Report of a case.
    Domen RE; Shaffer MB; Finke J; Sterin WK; Hurst CB
    Arch Intern Med; 1980 Feb; 140(2):262-3. PubMed ID: 6243459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Streptozotocin therapy for metastasizing insuloma].
    Seyer-Hansen K
    Ugeskr Laeger; 1974 Jan; 136(3):153-5. PubMed ID: 4362658
    [No Abstract]   [Full Text] [Related]  

  • 20. Secretory response and immunochemical heterogeneity of glucagon in plasma and tumor extracts of a patient with glucagonoma.
    Torre L; Vazquez JA; Blázquez E
    Horm Res; 1986; 23(3):159-66. PubMed ID: 3005153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.